לודוטרה 5 ישראל - עברית - Ministry of Health

לודוטרה 5

rafa laboratories ltd - prednisone 5 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness

לודוטרה 5 ישראל - עברית - Ministry of Health

לודוטרה 5

rafa laboratories ltd - prednisone 5 mg - tablets modified release - prednisone - for the treatment of moderate to severe, active rheumatoid arthritis in adults particularly when accompanied by morning stiffness

רייאטאז 200 מג ישראל - עברית - Ministry of Health

רייאטאז 200 מג

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

וידאזה ישראל - עברית - Ministry of Health

וידאזה

neopharm ltd - azacitidine - lyophilized powder for suspension for injection - azacitidine 100 mg/vial - azacitidine - azacitidine - for the treatment of patients with the following myelodysplastic syndromes subtypes: refractory anemia or refractory anemia with ringed sideroblasts ( if accompanied by neutropenia or thrombocytopenia or requiring transfusions),refractory anaemia with excess blasts, refractory anaemia with excess blasts in transformation, and chronic myelomonocytic leukaema.

וידאזה ישראל - עברית - Ministry of Health

וידאזה

neopharm ltd - azacitidine 100 mg - lyophilized powder for suspension for injection - azacitidine - for the treatment of patients with the following myelodysplastic syndromes subtypes: refractory anemia or refractory anemia with ringed sideroblasts ( if accompanied by neutropenia or thrombocytopenia or requiring transfusions),refractory anaemia with excess blasts, refractory anaemia with excess blasts in transformation, and chronic myelomonocytic leukaema.

ארביטוקס 5 מגמל ישראל - עברית - Ministry of Health

ארביטוקס 5 מגמל

merck serono ltd - cetuximab - תמיסה לאינפוזיה - cetuximab 5 mg/ml - cetuximab - cetuximab - erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (egfr) - expressing, kras wild-type metastatic colorectal cancer• in combination with irinotecan-based chemotherapy• in first-line in combination with folfox• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanerbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (scchn)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease

אקסיפן ישראל - עברית - Ministry of Health

אקסיפן

padagis israel pharmaceuticals ltd, israel - piroxicam - ג'ל - piroxicam 0.5 %w/w - piroxicam - piroxicam - for local treatment of inflammatory conditions accompanied by pain.

אקטיק 200 מקג ישראל - עברית - Ministry of Health

אקטיק 200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

אקטיק 600 מקג ישראל - עברית - Ministry of Health

אקטיק 600 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 600 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

אקטיק 1200 מקג ישראל - עברית - Ministry of Health

אקטיק 1200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 1200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.